Navigation Links
Hagens Berman Sobol Shapiro: Vytorin and Zetia Makers Settle Class-Action Suit With Proposed $41.5 Million
Date:8/5/2009

BOSTON, Aug. 5 /PRNewswire/ --- Attorneys representing consumers and third-party payors today announced a proposed $41.5 million settlement with drug manufacturers Merck & Co. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) to settle allegations the companies suppressed critical information about the efficacy and safety of prescription drugs Vytorin and Zetia. Merck and Schering-Plough previously settled similar claims with 35 states and the District of Columbia for $5.4 million.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO)

Hagens Berman Sobol Shapiro (HBSS), counsel for a nationwide class of third-party payors, brought the suit against manufacturers along with consumers in January 2008. Thomas M. Sobol, lead attorney on the case, hailed the agreement as an excellent result for plaintiffs.

"I am very pleased that we reached a comprehensive settlement that serves our clients' interest so well," Sobol said. "This settlement also reflects the vital role private litigation plays in holding pharmaceutical companies accountable when the FDA cannot."

Vytorin is the combination of prescription pills Zetia and Zocor, a statin available as a generic drug for about one-third the cost. The Food and Drug Administration (FDA) approved Zetia and Vytorin on the basis that the drugs reduced "bad" - or LDL - cholesterol. Defendants failed to present any evidence to the FDA that these drugs actually reduced the risk of heart disease or strokes.

Plaintiffs allege Merck and Schering-Plough created a joint venture in an attempt to protect profits from Zocor, Merck's hugely profitable cholesterol drug, which would otherwise lose patent protection in January 2006. In an effort to stem the eventual loss of sales to a generic form of Zocor, defendants marketed Vytorin as a single pill and an improvement over Zocor alone.

The lawsuit alleges that an internal study showed the combination-drug, Vytorin was actually less effective in reducing arterial plaque buildup than Zocor alone. The study also showed that Vytorin posed serious safety concerns. Plaintiffs claim the drug makers did not disclose the results of this study and instead sought to delay and conceal the negative results, causing consumers and third-party payors to pay for unnecessary prescriptions of Vytorin and Zetia.

The lawsuit, filed under the Racketeering Influenced and Corrupt Organizations Act (RICO), as well as the consumer protection statutes of New Jersey, California, Florida, Texas and Massachusetts is pending in United States District Court for the District of New Jersey.

The $41.5 million settlement is pending court approval. A preliminary approval hearing will be scheduled in the next month, followed by notice to members of the class.

You can review court documents on this case at www.hbsslaw.com.

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Boston, Los Angeles, Phoenix and San Francisco. Since the firm's founding in 1993, it has developed a nationally recognized practice in class action and complex litigation. Among recent successes, HBSS has negotiated a pending $300 million settlement as lead counsel in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees which is awaiting distribution; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS also served as counsel in a $850 million settlement in the Washington Public Power Supply litigation and represented Washington and 12 other states in lawsuits against the tobacco industry that resulted in the largest settlement in the history of litigation. For a complete listing of HBSS cases, visit www.hbsslaw.com.

    CONTACTS:

    Thomas M. Sobol (617) 482-3700
    Hagens Berman Sobol Shapiro
    Tom@hbsslaw.com

    Mark Firmani (206) 443-9357
    Firmani + Associates, Inc.
    Mark@firmani.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
2. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
3. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
4. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
5. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
6. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
7. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
8. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
9. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
10. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
11. Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: